Drug Search Results
More Filters [+]

Aderamastat

Alternative Names: Aderamastat, fp-025, fp025, fp 025
Latest Update: 2024-08-09
Latest Update Note: News Article

Product Description

Aderamastat is a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. MMP-12 plays a role in asthma pathophysiology and is associated with disease severity. Aderamastat showed sustained anti-inflammatory effects and attenuated allergen-induced histopathology in a mouse model of house dust-mite (HDM). Importantly, a Phase 2 allergen challenge asthma proof-of-concept study has been successfully completed. (Sourced from: https://www.benzinga.com/pressreleases/23/07/n33360879/foresee-pharmaceuticals-selected-for-late-breaking-oral-presentation-on-its-aderamastat-phase-2-st)

Mechanisms of Action: MMP12 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Foresee
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aderamastat

Countries in Clinic: Netherlands

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Asthma|Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FP02C-18-001

P2

Completed

Chronic Obstructive Pulmonary Disease|Asthma

2022-12-30

2017-005164-17

P2

Active, not recruiting

Asthma|Chronic Obstructive Pulmonary Disease

None

Recent News Events